Alzheimer's disease drug development pipeline: 2018

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Sleep disruption changes across the disease trajectory: Pilot findings from the healthy patterns sleep study Nancy A. Hodgson, Albert J. Safi Alzheimer's.

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Volume 1, Issue 1, Pages (June 2015)

Volume 3, Issue 4, Pages (November 2017)

Volume 3, Issue 1, Pages (January 2017)

Volume 3, Issue 1, Pages 1-9 (January 2017)

Relationship between high normal TSH levels and metabolic syndrome components in type 2 diabetic subjects with euthyroidism Lilit Petrosyan Journal.

Volume 1, Issue 3, Pages (November 2015)

Volume 3, Issue 3, Pages (September 2017)

Volume 1, Issue 1, Pages (June 2015)

Volume 3, Issue 2, Pages (June 2017)

Volume 3, Issue 2, Pages (June 2017)

Alzheimer's disease drug development pipeline: 2017

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review Christian Thoma, Christopher P. Day, Michael.

An amylin analog used as a challenge test for Alzheimer's disease

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Volume 2, Issue 1, Pages (January 2016)

Volume 3, Issue 1, Pages (January 2017)

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma M. Ashton, N. O'Rourke, N.

Antibiotics: A New Hope

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

T. Tedore British Journal of Anaesthesia

Refugee crisis and re-emergence of forgotten infections in Europe

Bernard Grenier Clinical Microbiology and Infection

Pain in cancer survivors; filling in the gaps

R. Cantón Clinical Microbiology and Infection

S. Imindu Liyanage, Clarissa Santos, Donald F. Weaver

Pathways to Primary Neurodegenerative Disease

Redefining Clinical Trials: The Age of Personalized Medicine

Type of anaesthesia and patient quality of recovery: a randomized trial comparing propofol–remifentanil total i.v. anaesthesia with desflurane anaesthesia

Vector control: a cornerstone in the malaria elimination campaign

Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery:

Delayed publication of clinical trials in cystic fibrosis

Controlled clinical trials in cystic fibrosis — are we doing better?

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

Volume 152, Issue 1, (January 2013)

Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study Kumar B. Rajan, Jennifer Weuve,

Levofloxacin in the treatment of ventilator-associated pneumonia

Scott A. Elman, James H. Ware, Alice B. Gottlieb, Joseph F. Merola

Symposia and Oral Presentations

T.M. File Clinical Microbiology and Infection

Antibacterial drug discovery in the 21st century

Abstracts cont. Clinical Microbiology and Infection

Current experience in treating invasive zygomycosis with posaconazole

Antimicrobial drug development – the past, the present, and the future

Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study Kumar B. Rajan, Jennifer Weuve,

Volume 17, Issue 2, Pages (February 1950)

Artefenomel: a promising new antimalarial drug

A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee T.J. Schnitzer, J.A. Marks Osteoarthritis.

Tuberculosis in HIV-infected patients: a comprehensive review

Table of contents The Journal for Nurse Practitioners

Volume 49, Issue 1, Pages v-vi (January 2018)

The atypical pneumonias: clinical diagnosis and importance

Modelling during an emergency: the 2009 H1N1 influenza pandemic

Cost minimization analysis on IV to oral conversion of antimicrobial agent by the clinical pharmacist intervention Dilip Chandrasekhar, Vikas PokkaVayalil

LIFESPAN OF ONE FOCUSED ULTRASOUND MEDIATED BLOOD-BRAIN BARRIER TREATMENT IN A MOUSE MODEL OF ALZHEIMER'S DISEASE Charissa Poon, Kullervo Hynynen Alzheimer's.

Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective Matthew Baumgart, Heather M. Snyder,

G.C. Schito Clinical Microbiology and Infection

Chronic widespread pain, including fibromyalgia: a pathway for care developed by the British Pain Society J. Lee, B. Ellis, C. Price, A.P. Baranowski

The Propranolol Aneurysm Trial Investigators

Volume 2, Issue 2, Pages (June 2016)

Impact of vitamin D on infectious disease-tuberculosis-a review

Volume 50, Issue 2, Pages iii-iv (April 2019)

News & Notes Journal of Allergy and Clinical Immunology

The future of diagnostic bacteriology

Volume 148, Issue 1, (January 2012)

Systematic review of methodology used in clinical studies evaluating the benefits of proton beam therapy Mercy Ofuya, Lucy McParland, Louise Murray,

Presentation transcript:

Alzheimer's disease drug development pipeline: 2018 Jeffrey Cummings, Garam Lee, Aaron Ritter, Kate Zhong Alzheimer's & Dementia: Translational Research & Clinical Interventions Volume 4, Pages 195-214 (January 2018) DOI: 10.1016/j.trci.2018.03.009 Copyright © 2018 The Authors Terms and Conditions

Fig. 1 Agents in clinical trials for treatment of Alzheimer's disease in 2018 (from clinicaltrials.gov accessed January 30, 2018). Alzheimer's & Dementia: Translational Research & Clinical Interventions 2018 4, 195-214DOI: (10.1016/j.trci.2018.03.009) Copyright © 2018 The Authors Terms and Conditions

Fig. 2 Mechanisms of action of agents in phase III. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2018 4, 195-214DOI: (10.1016/j.trci.2018.03.009) Copyright © 2018 The Authors Terms and Conditions

Fig. 3 Mechanisms of action of agents in phase II. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2018 4, 195-214DOI: (10.1016/j.trci.2018.03.009) Copyright © 2018 The Authors Terms and Conditions

Fig. 4 Site of action of anti-tau agents. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2018 4, 195-214DOI: (10.1016/j.trci.2018.03.009) Copyright © 2018 The Authors Terms and Conditions